Amyotrophic lateral sclerosis (ALS) still eludes all therapeutic efforts. In the past 10 years,
more than two dozen molecules have been studied, all with disappointing results. The …

Background We studied the safety and efficacy of lithium in combination with riluzole in ALS.
Recently, a pilot study demonstrated a dramatic effect of lithium in slowing ALS progression …

In a recent issue of The Lancet Neurology, Aggarwal et al.(Citation 1) reported a multicentric,
randomized, double-blind, clinical trial comparing lithium carbonate plus riluzole with …

Clinical trials in amyotrophic lateral sclerosis (ALS) remain stuck in a rut: so many trials, such
high expectations, such disappointing results. Since the trials of riluzole 15 years ago, 1 no …

Richard Bedlack hates the term “compassionate use”. It implies that people who are not in
favour of this often controversial practice are not compassionate, says the Duke University …

Recent studies of amyotrophic lateral sclerosis (ALS) have led to an expectation that
therapies will be found to stop progression of this disease, if not restore lost motor function …

Amyotrophic lateral sclerosis is a rare but fatal neurodegenerative disease, that typically
leads to muscle weakness, atrophy, and eventually respiratory failure within 2–4 years after …

After nearly a quarter century, Ton Fang and colleagues1 have provided a keen insight into
the mystery regarding the precise timing of the benefit of riluzole in the treatment of patients …

Comment 386 www. thelancet. com/neurology Vol 17 May 2018 might be an early transient
effect, with other molecular pathways becoming more involved later. Such a proposition …

Background Lithium has neuroprotective effects in cell and animal models of amyotrophic
lateral sclerosis (ALS), and a small pilot study in patients with ALS showed a significant …